Study guide
20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus
Philippine Physician Licensure Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: PLE Structure, Eligibility & Study Strategy
1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan
2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle
2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction
3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems
3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments
4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems
4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation
5 Chapter 5: Physiology IV: Neurophysiology & Special Senses
5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses
6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death
6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death
7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning
7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws
8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics
8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics
9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics
9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock
10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection
10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology
11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology
11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura
12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology
12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors
13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry
13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism
14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry
14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure
15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back
15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes
16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin
16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands
17 Chapter 17: Anatomy III: Head, Neck & Histology
17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology
18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections
18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis
19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections
19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning
20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections
20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases
21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections
21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis
22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding
22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage
23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems
23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception
24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception
24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria
25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues
25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents
26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections
26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections
27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders
27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning
28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders
28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child
29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider
29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036
30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine
30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine
31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer
31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health
32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics
32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections
33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics
33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy
34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics
34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis
35 Chapter 35: Surgery I: Basic Surgical Principles
35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety
36 Chapter 36: Surgery II: Abdomen, Breast & Hernia
36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma
37 Chapter 37: Surgery III: Surgical Specialties
37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)
38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine
38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome
39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine
39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS
40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry
40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)
20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus
Key Takeaways Explain This Topic AI
Dengue warning signs (abdominal pain, persistent vomiting, fluid accumulation, mucosal bleeding, lethargy, liver enlargement, rising hematocrit with falling platelets) call for admission and isotonic IV fluids.
Dengue NS1 antigen and RT-PCR are positive in the first days of fever, while IgM appears after about day 5.
P. vivax and P. ovale form liver hypnozoites, so radical cure needs 14 days of primaquine after G6PD testing.
Wuchereria bancrofti microfilariae show nocturnal periodicity, so blood smears are taken around midnight; annual MDA uses DEC plus albendazole.
Infectious mononucleosis shows heterophile antibodies and atypical CD8 T cells; ampicillin or amoxicillin causes a rash, and splenic rupture is a risk with contact sports.
Last updated: October 2026
Why this area matters
The TOS hematopoietic, lymphatic and immunologic area names:
- hemorrhagic fever;
- malaria;
- lymphogranuloma venereum;
Epstein-Barr virus.
Dengue is the most important of these in the Philippines. It is endemic in every region, peaks in the rainy season and fills pediatric wards during outbreaks. Malaria is close to elimination but still transmitted in Palawan, and lymphatic filariasis remains a target of mass drug administration. Board questions test:
- dengue classification and fluids;
- diagnostic tests by day of illness;
- Plasmodium species features and primaquine;
- filarial periodicity;
the EBV syndromes.
Arboviral Infections: Dengue Virus
Dengue virus (DENV) is an enveloped, single-stranded positive-sense RNA virus belonging to the family Flaviviridae , genus Flavivirus . It exists as four distinct, closely related serotypes: DENV-1, DENV-2, DENV-3, and DENV-4 . The primary vector across urban and peri-urban Philippine communities is Aedes aegypti (a day-biting, container-breeding mosquito marked by lyre-shaped thoracic stripes), with secondary transmission by Aedes albopictus .
Pathophysiology & Antibody-Dependent Enhancement (ADE)
Primary infection with one DENV serotype induces lifelong homotypic immunity to that specific serotype, but only short-lived (a few months) cross-protective heterotypic immunity to the remaining three serotypes. When an individual is infected years later by a heterologous serotype , pre-existing non-neutralizing antibodies bind to the new virions. Rather than clearing the virus, the antibody-virus complex binds via its Fc portion to Fc-gamma receptors on circulating monocytes and tissue macrophages .
This phenomenon— Antibody-Dependent Enhancement (ADE) —accelerates viral replication inside host macrophages by several logs. Infected macrophages release massive surges of inflammatory cytokines and chemical mediators (including tumor necrosis factor-alpha, interleukin-6, interleukin-8, and vascular endothelial growth factor). These mediators disrupt the endothelial glycocalyx and degrade tight junctions, precipitating sudden vascular hyperpermeability and capillary plasma leakage , which marks the transition to severe dengue.
Clinical Phases & DOH/WHO Triage Classification
Dengue characteristically evolves across three clinical phases:
Febrile Phase (Days 1 to 3): Sudden high fever ( 39 − 40 ∘ C 39-40^\circ\text{C} 39 − 4 0 ∘ C ), facial flushing, retro-orbital headache, severe arthralgia ("breakbone fever"), positive tourniquet test, and leukopenia.
Critical Phase (Days 3 to 7, usually around defervescence): Rapid plasma leakage into pleural and peritoneal cavities. Patients are categorized under Philippine DOH and WHO guidelines into three management groups:
Dengue without Warning Signs: Patients with fever plus any two of: nausea/vomiting, rash, aches and pains, tourniquet test positive, leukopenia.
Dengue with Warning Signs: Clinical indicators signaling impending plasma leakage and shock:
- Severe abdominal pain or tenderness
- Persistent vomiting
- Clinical fluid accumulation (pleural effusion, ascites)
- Mucosal bleeding (epistaxis, gingival bleeding, menorrhagia)
- Lethargy, restlessness, or altered sensorium
- Hepatomegaly greater than 2 cm below the costal margin
- Progressive increase in hematocrit concurrent with rapid decrease in platelet count
Severe Dengue: Manifested by:
Severe plasma leakage leading to Dengue Shock Syndrome (DSS) (narrow pulse pressure ≤ 20 mmHg \le 20\text{ mmHg} ≤ 20 mmHg , hypotension, prolonged capillary refill time) or respiratory distress
Severe bleeding (gastrointestinal hemorrhage evaluated by clinician)
Severe organ impairment (AST or ALT ≥ 1 , 000 U/L \ge 1,000\text{ U/L} ≥ 1 , 000 U/L , encephalopathy, myocarditis, acute kidney injury)
Recovery Phase (Days 7 to 10): Reabsorption of extravasated fluid, stabilization of hematocrit, return of appetite, and the appearance of a convalescent confluent erythematous rash with scattered round clearings ("islands of white in a sea of red") accompanied by intense pruritus.
Resuscitation & Fluid Management
For Dengue with Warning Signs , immediate hospital admission is mandatory. Intravenous fluid therapy must use isotonic crystalloids (0.9% normal saline or Ringer's lactate), initiated at 5 − 7 mL/kg/hour 5-7\text{ mL/kg/hour} 5 − 7 mL/kg/hour for 1 to 2 hours, titrating downward to 3 − 5 mL/kg/hour 3-5\text{ mL/kg/hour} 3 − 5 mL/kg/hour as perfusion and hematocrit improve. Hypotonic fluids (such as 0.45% NaCl or 5% dextrose in water) are contraindicated because they rapidly leave the vascular compartment, exacerbating third-space ascites and pleural effusions. Platelet transfusions are not recommended for thrombocytopenia alone and are reserved strictly for severe, life-threatening overt hemorrhage.
Dengue diagnosis and prevention in the Philippines
Diagnosis by day of illness:
- NS1 antigen and RT-PCR are positive during the first 5 days of fever;
- IgM appears from about day 5;
IgG rises rapidly in secondary infection.
Serial hematocrit and platelet counts track plasma leakage. A tourniquet test supports the diagnosis but cannot exclude it.
Monitoring: watch closely through the critical phase . Shock often occurs as fever falls.
What not to do:
- do not give NSAIDs or aspirin;
- do not give IM injections;
do not give steroids or prophylactic platelet transfusions.
Prevention: the DOH promotes the 4S strategy :
- S earch and destroy mosquito breeding sites;
- S ecure self-protection (repellents, long sleeves, screens);
- S eek early consultation;
S upport fogging or spraying only in hotspot areas.
Vaccine history: the school-based dengue vaccination program using CYD-TDV was stopped in 2017 . Data had shown a higher risk of severe dengue in vaccinated people who had never had dengue.
Other viral hemorrhagic fevers and arboviruses
Hantavirus:
carried by rodents and spread by inhaling their excreta;
causes hemorrhagic fever with renal syndrome, or a pulmonary syndrome.
Chikungunya and Zika are spread by Aedes mosquitoes.
Chikungunya causes high fever and severe, sometimes persistent, polyarthralgia.
Zika is usually mild but causes congenital microcephaly and is linked to Guillain-Barré syndrome.
Yellow fever , Ebola and Marburg are not endemic in the Philippines.
Travelers to yellow fever areas need vaccination and an international certificate.
Ebola is spread by contact with body fluids. It causes fever, vomiting, diarrhea and bleeding with high mortality, and needs strict infection control.
Blood & Tissue Protozoa: Plasmodium & Philippine Malaria Epidemiology
Malaria is caused by apicomplexan protozoa of the genus Plasmodium , transmitted to humans through the nocturnal bite of infected female Anopheles mosquitoes (the definitive hosts). In the Philippines, the primary vector is Anopheles flavirostris , which breeds in clean, slow-flowing, partly shaded foothill streams and bites mainly at night.
The Human Life Cycle
Exoerythrocytic (Hepatic) Phase: Mosquito inoculation introduces motile sporozoites into capillaries. Sporozoites reach the liver within 30 to 60 minutes, invading hepatocytes. Over 6 to 16 days, each sporozoite undergoes asexual multiplication ( hepatic schizogony ), forming an intrahepatic schizont containing thousands of merozoites . In P. vivax and P. ovale , a proportion of sporozoites differentiate into dormant hypnozoites , which remain quiescent in hepatocytes for months or years before awakening to cause true clinical relapses .
Erythrocytic Phase: Hepatic schizonts rupture, releasing merozoites into the bloodstream, which invade erythrocytes. Inside RBCs, merozoites develop from ring-form trophozoites into mature trophozoites, then into erythrocytic schizonts . Erythrocytic schizonts rupture, destroying the host RBC and discharging new merozoites, metabolic debris, and hemozoin pigment (malarial pigment) into the circulation. This rupture triggers massive host cytokine surges (TNF-alpha, IL-1), producing the classic malarial paroxysm (cold chills, high-spiking fever, followed by profuse diaphoresis). A subset of merozoites differentiate into sexual gametocytes , which are taken up by feeding mosquitoes during blood meals to complete sexual reproduction ( sporogony ).
Differential Features of Human Plasmodium Species
Feature Plasmodium falciparum Plasmodium vivax Plasmodium malariae Plasmodium ovale Plasmodium knowlesi
Erythrocyte Target Infects RBCs of all ages (can reach very high parasitemia) Infects mainly young RBCs ( reticulocytes ; parasitemia usually < 2%) Infects old, senescent RBCs only (parasitemia < 1%) Infects mainly reticulocytes (parasitemia usually < 2%) Infects RBCs of all ages (can achieve high parasitemia)
Infected RBC Appearance Normal size, normal shape Enlarged, pale , distorted Normal or slightly small Enlarged, oval-shaped with fimbriated (ragged) borders Normal size, normal shape
Erythrocyte Inclusions Maurer dots (clefts) Schüffner dots (fine pink granules) Ziemann dots Schüffner dots None prominent
Trophozoite Morphology Multiple delicate ring forms per RBC; appliqué / accolé forms (hugging RBC margin) Amoeboid, large, irregular ring forms Compact, horizontal "band" or "bar" forms stretching across the RBC Compact, round to oval Band forms resembling P. malariae
Gametocyte Morphology Pathognomonic crescent- or banana-shaped Large, round to oval Compact, round Round to oval Round
Paroxysm Periodicity Irregular, continuous, or subtertian (~48 hours) Benign tertian (strict 48-hour cycle) Quartan (strict 72-hour cycle) Benign tertian (48-hour cycle) Quotidian (rapid 24-hour cycle)
Hypnozoite Stage Absent (no late relapses; recrudescence occurs from surviving blood forms) Present (dormant hypnozoites cause late relapses; requires primaquine) Absent (can cause recrudescence decades later due to low-level blood carriage) Present (dormant hypnozoites cause late relapses; requires primaquine) Absent
Pathogenesis of Severe Plasmodium falciparum Malaria
Plasmodium falciparum is the most lethal malarial parasite because it infects erythrocytes of all ages, achieving astronomical parasite densities, and expresses the surface adhesion protein PfEMP-1 (Plasmodium falciparum erythrocyte membrane protein 1) . PfEMP-1 localizes to electron-dense "knobs" on the infected erythrocyte membrane, binding with high affinity to endothelial receptors—including ICAM-1 in the cerebral microvasculature, CD36 , and chondroitin sulfate A in the placenta.
This binding causes cytoadherence (infected RBCs adhering to capillary endothelium) and rosetting (infected RBCs binding uninfected RBCs), resulting in microvascular sequestration and complete capillary obstruction. This drives local tissue ischemia, lactic acidosis, and endothelial breakdown, manifesting as:
Cerebral Malaria: Severe encephalopathy, unarousable coma, generalized seizures, and cerebral edema.
Blackwater Fever: Massive, catastrophic intravascular hemolysis resulting in severe hemoglobinuria, turning the urine dark brown or black, rapidly precipitating acute tubular necrosis and oliguric renal failure.
Lactic Acidosis & Hypoglycemia: Lactic acidosis comes from microvascular obstruction and anaerobic glycolysis; hypoglycemia comes from parasite glucose consumption and impaired gluconeogenesis, and is worsened by quinine-induced hyperinsulinemia (especially in pregnancy).
Philippine Malaria Epidemiology & DOH Elimination Program
The Philippine malaria program has made steady progress toward elimination. By 2024, 72 of the country's 82 provinces were certified malaria-free and 9 more had recorded zero indigenous cases. Palawan remains the only province with sustained local transmission and the country's last hotspot. The Malaria Transition, Elimination and Sustainability Plan 2023 to 2028 targets zero cases in Palawan by 2026 and declaration of all provinces as malaria-free by 2030. Imported cases among overseas Filipino workers, seafarers, soldiers and travelers remain a reintroduction risk.
DOH Diagnostic & Therapeutic Guidelines
Gold Standard Diagnostics: Microscopic evaluation of Giemsa-stained Thick and Thin Blood Smears :
Thick Smear: RBCs are lysed during staining, concentrating parasites 20- to 30-fold; used for detecting parasite presence and quantifying parasite density (parasites/uL).
Thin Smear: Preserves intact red cell morphology with methanol fixation; used for species identification and differentiating developmental stages .
Rapid Diagnostic Tests (RDTs) detecting P. falciparum histidine-rich protein 2 (HRP-2) and pan-species lactate dehydrogenase (pLDH) are used in peripheral clinics.
First-Line Regimen for Uncomplicated P. falciparum : Artemisinin-based Combination Therapy ( ACT ). The Philippine DOH first-line regimen is Artemether-Lumefantrine (AL) (a 6-dose oral regimen given over 3 days). In addition, a single low dose of Primaquine (0.25 mg base/kg) is co-administered on Day 1 as a gametocidal agent to clear circulating gametocytes and prevent transmission to local mosquitoes (G6PD testing is not required for this single low gametocidal dose).
First-Line Regimen for P. vivax and Radical Cure: Chloroquine (the national regimen for vivax, 25 mg base/kg over 3 days) or AL for blood schizonts, combined with Primaquine (0.25 to 0.50 mg base/kg daily for 14 days) to eliminate dormant liver hypnozoites (radical cure). MANDATORY PRECAUTION: Prior to starting the 14-day primaquine course, patients must undergo G6PD screening . In individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency , primaquine generates intense intraerythrocytic oxidative stress, causing massive, life-threatening acute intravascular hemolytic anemia .
Severe Malaria Management: Intravenous Artesunate (2.4 mg/kg IV administered at 0, 12, and 24 hours, then once daily) is the first-line treatment of choice, transitioning to a full 3-day course of oral AL once the patient tolerates oral intake.
Lymphatic Filariasis in the Philippines
Lymphatic filariasis is a mosquito-borne disease caused by tissue nematodes that reside within human lymphatic vessels and lymph nodes.
Etiologic Agents & Vector Biology
Wuchereria bancrofti : The main cause of lymphatic filariasis in the Philippines. The primary rural vector is Aedes poicilius , an unusual night-biting mosquito that breeds preferentially in the water trapped in the axils of banana and abaca ( Musa textilis ) plants . Secondary vectors include Culex quinquefasciatus and Anopheles flavirostris .
Brugia malayi : A minor cause , found in a few swampy foci; transmitted mainly by Mansonia mosquitoes , which breed in freshwater swamps among aquatic plants such as Pistia .
Microfilarial Periodicity & Morphologic Differentiation
Microfilariae demonstrate strict nocturnal periodicity in peripheral blood, remaining sequestered deep in the pulmonary microvasculature during daylight hours and peaking in the peripheral circulation between 22:00 and 02:00 (synchronizing with vector biting habits). Diagnostic blood films must be drawn during this midnight window.
- Morphologic Feature Wuchereria bancrofti Microfilaria Brugia malayi Microfilaria
- Sheath Present Present
- Body Curves Smooth, sweeping, graceful curves Irregular, stiff, angular, crinkled curves
- Nuclear Column Discrete, clearly separated nuclei Blurred, overlapping, confluent nuclei
Tail Nuclei No nuclei in the terminal tail tip (tail tip is clear and pointed) Two distinct, separated terminal nuclei (one subterminal and one terminal swelling)
Clinical Progression & DOH Mass Drug Administration (MDA)
Asymptomatic Phase: Subclinical microfilaremia with progressive lymphatic dilation and microscopic hematuria/proteinuria.
Acute Phase: Acute Adenolymphangitis (ADL) presenting with high fever, chills, painful retrograde lymphangitis (inflammation spreading centrifugally down an extremity from proximal nodes), funiculitis, and acute epididymo-orchitis.
Chronic Phase: Irreversible lymphatic vessel obliteration leading to profound, non-pitting lymphedema, brawny induration, verrucous hyperkeratosis, and severe elephantiasis of the lower extremities, scrota, and labia; rupture of obstructed retroperitoneal lymphatics into the renal collecting system produces chyluria (milky white, lipid-rich urine).
National Elimination Strategy: The Philippine DOH implements annual Mass Drug Administration (MDA) in endemic provinces: single-dose Diethylcarbamazine citrate (DEC, 6 mg/kg) combined with Albendazole (400 mg) administered once annually for at least five consecutive years, accompanied by vector control and morbidity management (scrotal hydrocelectomy and limb hygiene to prevent secondary bacterial dermato-lymphangitis).
Lymphogranuloma venereum (LGV)
Cause: LGV is caused by the invasive Chlamydia trachomatis serovars L1, L2 and L3 , which infect macrophages and lymphatic tissue rather than only mucosal epithelium.
Primary stage: a small, painless papule or ulcer that heals quickly and is often unnoticed.
Secondary stage: painful, matted inguinal lymphadenopathy , 2 to 6 weeks later. Nodes above and below the inguinal ligament produce the groove sign , and they may form buboes that drain through sinuses.
Anorectal LGV: in men who have sex with men and in women it causes proctocolitis , with rectal pain, discharge and bleeding. Untreated, it can lead to strictures, fistulas and genital elephantiasis (esthiomene).
Diagnosis is by nucleic acid testing. Treatment is doxycycline 100 mg twice daily for 21 days , with aspiration of fluctuant nodes.
Epstein-Barr virus (EBV)
Biology: EBV is a herpesvirus that enters B cells through CD21 and remains latent in memory B cells. It spreads through saliva ("kissing disease").
Infectious mononucleosis:
mainly in adolescents and young adults;
fever, exudative pharyngitis , posterior cervical lymphadenopathy , fatigue, splenomegaly and hepatitis.
Lab findings are atypical lymphocytes (reactive CD8 T cells, called Downey cells) and heterophile antibodies (Monospot test). EBV-specific antibodies such as VCA IgM are used in young children.
Patients given ampicillin or amoxicillin often develop a maculopapular rash .
Patients should avoid contact sports for at least 3 weeks because the enlarged spleen can rupture.
EBV-associated tumors and lesions:
- Burkitt lymphoma (t(8;14), c-myc);
- nasopharyngeal carcinoma , common in Southeast Asia;
- Hodgkin lymphoma;
- primary CNS lymphoma in AIDS;
- post-transplant lymphoproliferative disorder;
oral hairy leukoplakia in HIV.
X-linked lymphoproliferative disease causes fatal mononucleosis in boys with an inherited immune defect.